17. 多系統萎縮症
［臨床試験数：107，薬物数：153（DrugBank：48），標的遺伝子数：59，標的パスウェイ数：104］
Searched query = "Multiple system atrophy", "MSA-C", "MSA-P", "Olivopontocerebellar atrophy", "OPCA", "Striatonigral degeneration", "Shy-Drager syndrome"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04468919 (ClinicalTrials.gov) | July 1, 2021 | 8/7/2020 | Optimizing BCI-FIT: Brain Computer Interface - Functional Implementation Toolkit | Optimizing BCI-FIT: Brain Computer Interface - Functional Implementation Toolkit | Amyotrophic Lateral Sclerosis;Brainstem Stroke;Muscular Dystrophies;Parkinson's Disease and Parkinsonism;Multiple System Atrophy;Brain Tumor Adult;Spinal Cord Injuries;Locked-in Syndrome | Behavioral: BCI-FIT multi-modal access;Behavioral: BCI-FIT adaptive signal modeling;Behavioral: BCI-FIT active querying;Behavioral: BCI-FIT language modeling | Oregon Health and Science University | NULL | Not yet recruiting | 18 Years | 75 Years | All | 60 | N/A | United States |
| 2 | NCT04616456 (ClinicalTrials.gov) | December 2020 | 26/10/2020 | Effect of Verdiperstat on Microglial Activation in Well-characterized MSA Patients | Effect of Verdiperstat on Microglial Activation in Well-characterized MSA Patients | Multiple System Atrophy;Multiple System Atrophy, Cerebellar Variant;Multiple System Atrophy, Parkinson Variant (Disorder);Multiple System Atrophy (MSA) With Orthostatic Hypotension | Drug: [F-18]PBR06;Drug: Verdiperstat | Brigham and Women's Hospital | Biohaven Pharmaceuticals, Inc. | Not yet recruiting | 18 Years | N/A | All | 8 | Early Phase 1 | United States |
| 3 | NCT04620382 (ClinicalTrials.gov) | November 9, 2020 | 27/10/2020 | Effect of Midodrine vs Abdominal Compression on Cardiovascular Risk Markers in Autonomic Failure Patients | Effect of Midodrine vs Abdominal Compression on Cardiovascular Risk Markers in Autonomic Failure Patients | Neurogenic Orthostatic Hypotension;Autonomic Failure;Pure Autonomic Failure;Multiple System Atrophy;Parkinson Disease | Drug: Midodrine;Drug: Placebo pill;Device: Abdominal compression;Device: sham compression | Vanderbilt University Medical Center | NULL | Recruiting | 40 Years | 80 Years | All | 31 | Early Phase 1 | United States |
| 4 | NCT04250493 (ClinicalTrials.gov) | October 28, 2020 | 29/1/2020 | Insulin Resistance in Multiple System Atrophy | Insulin Resistance in Multiple System Atrophy | Multiple System Atrophy | Biological: Homeostasis Model Assessment of insulin resistance (HOMA);Behavioral: MOntreal Cognitive Assessment (MoCA);Behavioral: Clinical characteristics of AMS patients;Procedure: Brain Magnetic Resonance Imaging (MRI);Biological: Blood sampling | University Hospital, Bordeaux | Université de Bordeaux;Labex Brain;Centre National de la Recherche Scientifique, France | Recruiting | 30 Years | N/A | All | 124 | N/A | France |
| 5 | NCT04431713 (ClinicalTrials.gov) | September 16, 2020 | 29/5/2020 | Exenatide Once-weekly as a Treatment for Multiple System Atrophy | An Open Label, Single Site, 48 Week, Randomised Controlled Trial Evaluating the Safety and Efficacy of Exenatide Once-weekly in the Treatment of Patients With Multiple System Atrophy | Multiple System Atrophy | Drug: Exenatide Pen Injector [Bydureon] | University College, London | NULL | Recruiting | 30 Years | 80 Years | All | 50 | Phase 2 | United Kingdom |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 6 | NCT04165486 (ClinicalTrials.gov) | July 7, 2020 | 14/11/2019 | Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of BIIB101 Administered to Adults With Multiple System Atrophy | A Phase 1 Study to Assess the Safety, Tolerability, and Pharmacokinetics of BIIB101 Administered Intrathecally to Adults With Multiple System Atrophy | Multiple System Atrophy | Drug: BIIB101;Drug: Placebo | Biogen | NULL | Recruiting | 40 Years | 70 Years | All | 34 | Phase 1 | Austria;France;Germany;Portugal;United Kingdom |
| 7 | NCT04193527 (ClinicalTrials.gov) | July 2020 | 2/12/2019 | A Study to Evaluate the Diagnostic Efficacy of DaTSCAN™ Ioflupane (123I) Injection in Single Photon Emission Computed Tomography (SPECT) for the Diagnosis of Parkinsonian Syndrome (PS) in Chinese Patients | A Multicentre, Phase 3, Clinical Study to Compare the Striatal Uptake of a Dopamine Transporter Radioligand, DaTSCAN™ Ioflupane (123I) Injection, After Intravenous Administration to Chinese Patients With a Diagnosis of Parkinson's Disease, Multiple System Atrophy, Progressive Supranuclear Palsy, or Essential Tremor and to Healthy Controls | Parkinsonian Syndrome;Parkinson Disease(PD);Multiple System Atrophy (MSA);Progressive Supranuclear Palsy (PSP) | Drug: DaTSCAN™ Ioflupane (123I) Injection | GE Healthcare | PPD | Not yet recruiting | 40 Years | 80 Years | All | 172 | Phase 3 | China |
| 8 | ChiCTR2000033282 | 2020-06-01 | 2020-05-26 | Construction of cohort and prognosis prediction model of multiple system atrophy | Construction of cohort and prognosis prediction model of multiple system atrophy | Multiple system atrophy | Gold Standard:Clinical outcomes.;Index test:Prognosis prediction model of multiple system atrophy; | West China Hospital of Sichuan University | NULL | Recruiting | 30 | 75 | Both | Target condition:600;Difficult condition:0 | China | |
| 9 | EUCTR2020-000122-26-GB (EUCTR) | 11/05/2020 | 06/04/2020 | Exenatide once-weekly as a treatment for Multiple System Atrophy. | A Phase IIa, open label, single-site, 48 week randomised controlled trial evaluating the safety and efficacy of Exenatide once-weekly in the treatment of patients with Multiple System Atrophy - Exenatide once-weekly as a treatment for Multiple System Atrophy. | Multiple System Atrophy MedDRA version: 21.1;Level: PT;Classification code 10064060;Term: Multiple system atrophy;System Organ Class: 10029205 - Nervous system disorders | Trade Name: Bydureon Product Name: Bydureon INN or Proposed INN: Exenatide | University College London (UCL) | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 50 | Phase 2 | United Kingdom | ||
| 10 | EUCTR2018-003941-41-AT (EUCTR) | 05/03/2020 | 19/06/2019 | This study will look at whether an investigational drug, called TD-9855, works and how safe it is when taken over a longer period of time to treat symptomatic neurogenic orthostatic hypotension (snOH) in people with Parkinson’s disease (PD), multiple system atrophy (MSA), or pure autonomic failure (PAF). It will also look at the effects of TD-9855 on general well-being and whether it can improve symptoms of neurogenic OH (nOH) | A Phase 3, 22-week, Multi-center, Randomized Withdrawal Study of TD-9855 in Treating Symptomatic NeurogenicOrthostatic Hypotension in Subjects with Primary Autonomic Failure - Redwood | Symptomatic Neurogenic Orthostatic Hypotension in Subjects with Primary Autonomic Failure;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Code: TD-9855 INN or Proposed INN: ampreloxetine hydrochloride Other descriptive name: TD-9855 | Theravance Biopharma Ireland Limited | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 258 | Phase 3 | United States;Portugal;Estonia;Spain;Ukraine;Austria;Russian Federation;Chile;Israel;United Kingdom;Italy;France;Hungary;Mexico;Canada;Argentina;Poland;Peru;Australia;Denmark;Bulgaria;Germany;New Zealand | ||
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 11 | NCT04246437 (ClinicalTrials.gov) | February 4, 2020 | 25/1/2020 | [18F]F-DOPA Imaging in Patients With Autonomic Failure | [18F]F-DOPA Imaging in Patients With Autonomic Failure | Autonomic Failure;Pure Autonomic Failure;Parkinson Disease;Multiple System Atrophy;Dementia With Lewy Bodies | Drug: [18F]FDOPA;Drug: Carbidopa 200mg oral dose;Drug: Entacapone 400mg oral dose | Daniel Claassen | NULL | Recruiting | 18 Years | N/A | All | 40 | Phase 1 | United States |
| 12 | EUCTR2018-003941-41-PT (EUCTR) | 03/02/2020 | 21/08/2019 | This study will look at whether an investigational drug, called TD-9855, works and how safe it is when taken over a longer period of time to treat symptomatic neurogenic orthostatic hypotension (snOH) in people with Parkinson’s disease (PD), multiple system atrophy (MSA), or pure autonomic failure (PAF). It will also look at the effects of TD-9855 on general well-being and whether it can improve symptoms of neurogenic OH (nOH) | A Phase 3, 22-week, Multi-center, Randomized Withdrawal Study of TD-9855 in Treating Symptomatic NeurogenicOrthostatic Hypotension in Subjects with Primary Autonomic Failure - Redwood | Symptomatic Neurogenic Orthostatic Hypotension in Subjects with Primary Autonomic Failure MedDRA version: 20.0;Level: LLT;Classification code 10021102;Term: Hypotension orthostatic symptomatic;System Organ Class: 100000004866;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Code: TD-9855 INN or Proposed INN: ampreloxetine hydrochloride Other descriptive name: TD-9855 | Theravance Biopharma Ireland Limited | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 258 | Phase 3 | Portugal;United States;Estonia;Spain;Ukraine;Austria;Russian Federation;Israel;Italy;United Kingdom;France;Hungary;Canada;Poland;Australia;Denmark;Bulgaria;Germany;New Zealand | ||
| 13 | EUCTR2018-003289-15-DE (EUCTR) | 28/01/2020 | 08/02/2019 | This study will look at whether an investigational drug called TD-9855 works and how safe it is for treating symptomatic neurogenic orthostatic hypotension (snOH) in people with Parkinson’s disease (PD), multiple system atrophy (MSA) or pure autonomic failure (PAF) | A Phase 3, 4-week, Multicenter, Randomized, Double-blind,Placebo-controlled, Parallel-group Study of TD-9855 inTreating Symptomatic Neurogenic Orthostatic Hypotension inSubjects With Primary Autonomic Failure - Phase 3 Clinical Effect of TD-9855 for Treating snOH in Subjects With Primary Autonomic Failure | Symptomatic Neurogenic Orthostatic Hypotension in Subjects with Primary Autonomic Failure;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Code: TD-9855 INN or Proposed INN: ampreloxetine Other descriptive name: TD-9855 | Theravance Biopharma Ireland Limited | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 188 | Phase 3 | Portugal;United States;Estonia;Spain;Ukraine;Austria;Israel;Russian Federation;United Kingdom;Italy;France;Czech Republic;Hungary;Canada;Poland;Denmark;Bulgaria;Germany | ||
| 14 | EUCTR2018-003289-15-PT (EUCTR) | 13/01/2020 | 21/08/2019 | This study will look at whether an investigational drug called TD-9855 works and how safe it is for treating symptomatic neurogenic orthostatic hypotension (snOH) in people with Parkinson’s disease (PD), multiple system atrophy (MSA) or pure autonomic failure (PAF) | A Phase 3, 4-week, Multicenter, Randomized, Double-blind,Placebo-controlled, Parallel-group Study of TD-9855 inTreating Symptomatic Neurogenic Orthostatic Hypotension inSubjects With Primary Autonomic Failure - Sequoia study | Symptomatic Neurogenic Orthostatic Hypotension in Subjects with Primary Autonomic Failure;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Code: TD-9855 INN or Proposed INN: ampreloxetine hydrochloride | Theravance Biopharma Ireland Limited | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 188 | Phase 3 | Portugal;United States;Estonia;Spain;Ukraine;Austria;Russian Federation;Israel;Chile;Italy;United Kingdom;France;Hungary;Mexico;Canada;Argentina;Poland;Peru;Australia;Denmark;Bulgaria;Germany;New Zealand | ||
| 15 | EUCTR2019-001100-38-DE (EUCTR) | 07/01/2020 | 07/10/2019 | A study to assess whether a drug called BHV-3241 works and is safe to use in people with Multiple System Atrophy (M-STAR Study) | Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of BHV-3241 in Subjects with Multiple System Atrophy (M-STAR Study) | Multiple System Atrophy MedDRA version: 21.1;Level: PT;Classification code 10064060;Term: Multiple system atrophy;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: BHV-3241 INN or Proposed INN: Verdiperstat | Biohaven Pharmaceuticals, Inc | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 422 | Phase 3 | United States;France;Austria;Germany;United Kingdom;Italy;China | ||
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 16 | NCT03446807 (ClinicalTrials.gov) | January 2020 | 20/2/2018 | Safety and Efficacy of Droxidopa for Fatigue in Patients With Parkinsonism | Safety and Efficacy of Droxidopa for Fatigue in Patients With Parkinsonism | Parkinson Disease;Multiple System Atrophy;Progressive Supranuclear Palsy | Drug: Droxidopa;Drug: Placebo Oral Tablet | Loma Linda University | H. Lundbeck A/S | Not yet recruiting | 50 Years | N/A | All | 32 | Phase 2 | United States |
| 17 | EUCTR2019-001100-38-AT (EUCTR) | 20/12/2019 | 29/10/2019 | A study to assess whether a drug called BHV-3241 works and is safe to use in people with Multiple System Atrophy (M-STAR Study) | Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of BHV-3241 in Subjects with Multiple System Atrophy (M-STAR Study) | Multiple System Atrophy MedDRA version: 21.1;Level: PT;Classification code 10064060;Term: Multiple system atrophy;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: BHV-3241 INN or Proposed INN: Verdiperstat | Biohaven Pharmaceuticals, Inc | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 422 | Phase 3 | United States;France;Austria;Germany;United Kingdom;Italy;China | ||
| 18 | EUCTR2019-001100-38-FR (EUCTR) | 13/12/2019 | 03/10/2019 | A study to assess whether a drug called BHV-3241 works and is safe to use in people with Multiple System Atrophy(M-STAR Study) | Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of BHV-3241 in Subjects with Multiple System Atrophy (M-STAR Study) | Multiple System Atrophy MedDRA version: 21.1;Level: PT;Classification code 10064060;Term: Multiple system atrophy;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: BHV-3241 INN or Proposed INN: Verdiperstat | Biohaven Pharmaceuticals, Inc | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 252 | Phase 3 | United States;France;Austria;Germany;Italy;United Kingdom | ||
| 19 | EUCTR2019-001100-38-GB (EUCTR) | 06/12/2019 | 11/10/2019 | A study to assess whether a drug called BHV-3241 works and is safe to use in people with Multiple System Atrophy(M-STAR Study) | Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of BHV-3241 in Subjects with Multiple System Atrophy (M-STAR Study) | Multiple System Atrophy MedDRA version: 21.1;Level: PT;Classification code 10064060;Term: Multiple system atrophy;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: BHV-3241 INN or Proposed INN: Verdiperstat | Biohaven Pharmaceuticals, Inc | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 422 | Phase 3 | United States;France;Austria;Germany;Italy;United Kingdom | ||
| 20 | EUCTR2018-003941-41-DK (EUCTR) | 29/10/2019 | 24/06/2019 | This study will look at whether an investigational drug, called TD-9855, works and how safe it is when taken over a longer period of time to treat symptomatic neurogenic orthostatic hypotension (snOH) in people with Parkinson’s disease (PD), multiple system atrophy (MSA), or pure autonomic failure (PAF). It will also look at the effects of TD-9855 on general well-being and whether it can improve symptoms of neurogenic OH (nOH) | A Phase 3, 22-week, Multi-center, Randomized Withdrawal Study of TD-9855 in Treating Symptomatic Neurogenic Orthostatic Hypotension in Subjects with Primary Autonomic Failure - Redwood | Symptomatic Neurogenic Orthostatic Hypotension in Subjects with Primary Autonomic Failure;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Theravance Biopharma Ireland Limited | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 258 | Phase 3 | United States;Estonia;Spain;Ukraine;Austria;Russian Federation;Israel;Italy;United Kingdom;France;Hungary;Canada;Poland;Denmark;Australia;Bulgaria;Germany;New Zealand | |||
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 21 | EUCTR2018-003941-41-BG (EUCTR) | 10/10/2019 | 26/06/2019 | This study will look at whether an investigational drug, called TD-9855, works and how safe it is when taken over a longer period of time to treat symptomatic neurogenic orthostatic hypotension (snOH) in people with Parkinson’s disease (PD), multiple system atrophy (MSA), or pure autonomic failure (PAF). It will also look at the effects of TD-9855 on general well-being and whether it can improve symptoms of neurogenic OH (nOH) | A Phase 3, 22-week, Multi-center, Randomized Withdrawal Study of TD-9855 in Treating Symptomatic NeurogenicOrthostatic Hypotension in Subjects with Primary Autonomic Failure - Redwood | Symptomatic Neurogenic Orthostatic Hypotension in Subjects with Primary Autonomic Failure;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Code: TD-9855 INN or Proposed INN: ampreloxetine hydrochloride Other descriptive name: TD-9855 | Theravance Biopharma Ireland Limited | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 258 | Phase 3 | United States;Portugal;Estonia;Spain;Ukraine;Austria;Russian Federation;Chile;Israel;United Kingdom;Italy;France;Hungary;Mexico;Canada;Argentina;Poland;Peru;Australia;Denmark;Bulgaria;Germany;New Zealand | ||
| 22 | EUCTR2018-003289-15-BG (EUCTR) | 10/10/2019 | 24/07/2019 | This study will look at whether an investigational drug called TD-9855 works and how safe it is for treating symptomatic neurogenic orthostatic hypotension (snOH) in people with Parkinson’s disease (PD), multiple system atrophy (MSA) or pure autonomic failure (PAF) | A Phase 3, 4-week, Multicenter, Randomized, Double-blind,Placebo-controlled, Parallel-group Study of TD-9855 inTreating Symptomatic Neurogenic Orthostatic Hypotension inSubjects With Primary Autonomic Failure - Sequoia study | Symptomatic Neurogenic Orthostatic Hypotension in Subjects with Primary Autonomic Failure;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Code: TD-9855 INN or Proposed INN: ampreloxetine hydrochloride | Theravance Biopharma Ireland Limited | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 188 | Phase 3 | United States;Portugal;Estonia;Spain;Ukraine;Austria;Russian Federation;Chile;Israel;United Kingdom;Italy;France;Hungary;Mexico;Canada;Argentina;Poland;Peru;Australia;Denmark;Bulgaria;Germany;New Zealand | ||
| 23 | NCT04184063 (ClinicalTrials.gov) | September 16, 2019 | 29/7/2019 | Study of NBMI Treatment in Patients With Atypical Parkinsons (PSP or MSA) | A Pilot Exploratory, Randomised, Placebo-controlled, Double Blinded, Cross-over , Phase 2a Study to Explore Efficacy and Safety of NBMI Treatment in Patients With Progressive Supranuclear Palsy (PSP) or Multiple System Atrophy (MSA) | Progressive Supranuclear Palsy;Multiple System Atrophy | Drug: NBMI;Other: Placebo | EmeraMed | NULL | Recruiting | 40 Years | 85 Years | All | 16 | Phase 2 | Slovenia |
| 24 | NCT03753763 (ClinicalTrials.gov) | September 9, 2019 | 19/11/2018 | Safinamide for Multiple System Atrophy (MSA) | 12-weeks, Multicentre, Randomized, Double-blind, Placebo-controlled, Exploratory, Pilot Study to Evaluate the Safety and Efficacy of Safinamide 200 mg OD, as add-on Therapy, in Patients With Possible or Probable Parkinsonian Variant of MSA | Multiple System Atrophy | Drug: Safinamide Methanesulfonate;Drug: Safinamide Methanesulfonate matching placebo | Zambon SpA | NULL | Active, not recruiting | 30 Years | 80 Years | All | 49 | Phase 2 | Italy;Spain |
| 25 | EUCTR2018-003941-41-PL (EUCTR) | 23/08/2019 | 03/06/2019 | This study will look at whether an investigational drug, called TD-9855, works and how safe it is when taken over a longer period of time to treat symptomatic neurogenic orthostatic hypotension (snOH) in people with Parkinson’s disease (PD), multiple system atrophy (MSA), or pure autonomic failure (PAF). It will also look at the effects of TD-9855 on general well-being and whether it can improve symptoms of neurogenic OH (nOH) | A Phase 3, 22-week, Multi-center, Randomized Withdrawal Study of TD-9855 in Treating Symptomatic NeurogenicOrthostatic Hypotension in Subjects with Primary Autonomic Failure - Redwood | Symptomatic Neurogenic Orthostatic Hypotension in Subjects with Primary Autonomic Failure;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Code: TD-9855 INN or Proposed INN: ampreloxetine hydrochloride Other descriptive name: TD-9855 | Theravance Biopharma Ireland Limited | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 258 | Phase 3 | Portugal;United States;Estonia;Spain;Ukraine;Austria;Israel;Russian Federation;United Kingdom;Italy;France;Hungary;Canada;Poland;Australia;Denmark;Bulgaria;Germany;New Zealand | ||
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 26 | NCT04004819 (ClinicalTrials.gov) | August 15, 2019 | 27/6/2019 | Rituximab for Multiple System Atrphy | Rituximab Therapy for the Patients With Multiple Syetem Atrophy | Multiple System Atrophy | Drug: Rituximab | First Affiliated Hospital of Fujian Medical University | NULL | Recruiting | 18 Years | 80 Years | All | 50 | Phase 2 | China |
| 27 | EUCTR2018-003941-41-ES (EUCTR) | 13/08/2019 | 11/06/2019 | This study will look at whether an investigational drug, called TD-9855, works and how safe it is when taken over a longer period of time to treat symptomatic neurogenic orthostatic hypotension (snOH) in people with Parkinson’s disease (PD), multiple system atrophy (MSA), or pure autonomic failure (PAF). It will also look at the effects of TD-9855 on general well-being and whether it can improve symptoms of neurogenic OH (nOH) | A Phase 3, 22-week, Multi-center, Randomized Withdrawal Study of TD-9855 in Treating Symptomatic NeurogenicOrthostatic Hypotension in Subjects with Primary Autonomic Failure - Redwood | Symptomatic Neurogenic Orthostatic Hypotension in Subjects with Primary Autonomic Failure;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Code: TD-9855 INN or Proposed INN: ampreloxetine hydrochloride Other descriptive name: TD-9855 | Theravance Biopharma Ireland Limited | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 258 | Phase 3 | United States;Estonia;Spain;Ukraine;Austria;Russian Federation;Israel;Italy;United Kingdom;France;Hungary;Canada;Poland;Australia;Denmark;Bulgaria;Germany;New Zealand | ||
| 28 | EUCTR2018-003941-41-GB (EUCTR) | 09/08/2019 | 16/05/2019 | This study will look at whether an investigational drug, called TD-9855, works and how safe it is when taken over a longer period of time to treat symptomatic neurogenic orthostatic hypotension (snOH) in people with Parkinson’s disease (PD), multiple system atrophy (MSA), or pure autonomic failure (PAF). It will also look at the effects of TD-9855 on general well-being and whether it can improve symptoms of neurogenic OH (nOH) | A Phase 3, 22-week, Multi-center, Randomized Withdrawal Study of TD-9855 in Treating Symptomatic Neurogenic Orthostatic Hypotension in Subjects with Primary Autonomic Failure - Redwood | Symptomatic Neurogenic Orthostatic Hypotension in Subjects with Primary Autonomic Failure;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Code: TD-9855 INN or Proposed INN: ampreloxetine hydrochloride Other descriptive name: TD-9855 | Theravance Biopharma Ireland Limited | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 258 | Phase 3 | United States;Portugal;Estonia;Spain;Ukraine;Austria;Russian Federation;Chile;Israel;Italy;United Kingdom;France;Hungary;Mexico;Canada;Argentina;Poland;Peru;Australia;Denmark;Bulgaria;Germany;New Zealand | ||
| 29 | EUCTR2018-003941-41-HU (EUCTR) | 30/07/2019 | 01/08/2019 | This study will look at whether an investigational drug, called TD-9855, works and how safe it is when taken over a longer period of time to treat symptomatic neurogenic orthostatic hypotension (snOH) in people with Parkinson’s disease (PD), multiple system atrophy (MSA), or pure autonomic failure (PAF). It will also look at the effects of TD-9855 on general well-being and whether it can improve symptoms of neurogenic OH (nOH) | A Phase 3, 22-week, Multi-center, Randomized Withdrawal Study of TD-9855 in Treating Symptomatic Neurogenic Orthostatic Hypotension in Subjects with Primary Autonomic Failure - Redwood | Symptomatic Neurogenic Orthostatic Hypotension in Subjects with Primary Autonomic Failure;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Theravance Biopharma Ireland Limited | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 258 | Phase 3 | United States;Estonia;Spain;Ukraine;Austria;Russian Federation;Israel;Italy;United Kingdom;France;Hungary;Canada;Poland;Australia;Denmark;Bulgaria;Germany;New Zealand | |||
| 30 | NCT03952806 (ClinicalTrials.gov) | July 29, 2019 | 15/5/2019 | Study of BHV-3241 in Subjects With Multiple System Atrophy | A Randomized, Double-Blind, Placebo-Controlled, Parallel- Group Study to Evaluate the Efficacy and Safety of BHV-3241 in Subjects With Multiple System Atrophy (M-STAR Study) | Multiple System Atrophy | Drug: Verdiperstat;Drug: Placebo | Biohaven Pharmaceuticals, Inc. | NULL | Active, not recruiting | 40 Years | 80 Years | All | 336 | Phase 3 | United States;Austria;France;Germany;Italy;United Kingdom |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 31 | EUCTR2018-004145-16-ES (EUCTR) | 24/07/2019 | 11/06/2019 | A study evaluating the safety and efficacy of safinamide for patients with Multiple System Atrophy | A 12-weeks, multicentre, randomized, double-blind, placebo-controlled, exploratory, pilot study to evaluate the safety and efficacy of safinamide 200 mg once daily, as add-on therapy, in patients with possible or probable parkinsonian variant of multiple system atrophy. - Safinamide for Multiple System Atrophy | Parkinsonian variant of Multiple System Atrophy MedDRA version: 20.0;Level: PT;Classification code 10064060;Term: Multiple system atrophy;System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Zambon SpA | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 48 | Phase 2 | Spain | |||
| 32 | EUCTR2018-003289-15-PL (EUCTR) | 19/07/2019 | 07/05/2019 | This study will look at whether an investigational drug called TD-9855 works and how safe it is for treating symptomatic neurogenic orthostatic hypotension (snOH) in people with Parkinson’s disease (PD), multiple system atrophy (MSA) or pure autonomic failure (PAF) | A Phase 3, 4-week, Multicenter, Randomized, Double-blind,Placebo-controlled, Parallel-group Study of TD-9855 inTreating Symptomatic Neurogenic Orthostatic Hypotension inSubjects With Primary Autonomic Failure - Phase 3 Clinical Effect of TD-9855 for Treating snOH in Subjects With Primary Autonomic Failure | Symptomatic Neurogenic Orthostatic Hypotension in Subjects with Primary Autonomic Failure;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Code: TD-9855 INN or Proposed INN: ampreloxetine chydrochloride Other descriptive name: TD-9855 | Theravance Biopharma Ireland Limited | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 188 | Phase 3 | United States;Portugal;Czechia;Estonia;Spain;Ukraine;Austria;Russian Federation;Chile;Israel;United Kingdom;Italy;France;Hungary;Mexico;Canada;Argentina;Poland;Peru;Australia;Denmark;Bulgaria;Germany;New Zealand | ||
| 33 | EUCTR2018-003941-41-EE (EUCTR) | 04/07/2019 | 29/05/2019 | This study will look at whether an investigational drug, called TD-9855, works and how safe it is when taken over a longer period of time to treat symptomatic neurogenic orthostatic hypotension (snOH) in people with Parkinson’s disease (PD), multiple system atrophy (MSA), or pure autonomic failure (PAF). It will also look at the effects of TD-9855 on general well-being and whether it can improve symptoms of neurogenic OH (nOH) | A Phase 3, 22-week, Multi-center, Randomized Withdrawal Study of TD-9855 in Treating Symptomatic Neurogenic Orthostatic Hypotension in Subjects with Primary Autonomic Failure - Redwood | Symptomatic Neurogenic Orthostatic Hypotension in Subjects with Primary Autonomic Failure;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Theravance Biopharma Ireland Limited | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 258 | Phase 3 | United States;Estonia;Spain;Ukraine;Austria;Russian Federation;Israel;Italy;United Kingdom;France;Hungary;Canada;Poland;Australia;Denmark;Bulgaria;Germany;New Zealand | |||
| 34 | EUCTR2018-003289-15-DK (EUCTR) | 02/07/2019 | 14/03/2019 | This study will look at whether an investigational drug called TD-9855 works and how safe it is for treating symptomatic neurogenic orthostatic hypotension (snOH) in people with Parkinson’s disease (PD), multiple system atrophy (MSA) or pure autonomic failure (PAF) | A Phase 3, 4-week, Multicenter, Randomized, Double-blind,Placebo-controlled, Parallel-group Study of TD-9855 inTreating Symptomatic Neurogenic Orthostatic Hypotension inSubjects With Primary Autonomic Failure - Sequoia study | Symptomatic Neurogenic Orthostatic Hypotension in Subjects with Primary Autonomic Failure;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Code: TD-9855 INN or Proposed INN: ampreloxetine hydrochloride | Theravance Biopharma Ireland Limited | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 188 | Phase 3 | United States;Portugal;Estonia;Spain;Ukraine;Austria;Russian Federation;Chile;Israel;United Kingdom;Italy;France;Hungary;Mexico;Canada;Argentina;Poland;Peru;Denmark;Australia;Bulgaria;Germany;New Zealand | ||
| 35 | EUCTR2018-003289-15-ES (EUCTR) | 26/06/2019 | 27/06/2019 | This study will look at whether an investigational drug called TD-9855 works and how safe it is for treating symptomatic neurogenic orthostatic hypotension (snOH) in people with Parkinson’s disease (PD), multiple system atrophy (MSA) or pure autonomic failure (PAF) | A Phase 3, 4-week, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study of TD-9855 in Treating Symptomatic Neurogenic Orthostatic Hypotension in Subjects With Primary Autonomic Failure - Phase 3 Clinical Effect of TD-9855 for Treating snOH in Subjects With Primary Autonomic Failure | Symptomatic Neurogenic Orthostatic Hypotension in Subjects with Primary Autonomic Failure;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Theravance Biopharma Ireland Limited | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 188 | Phase 3 | United States;Estonia;Spain;Ukraine;Austria;Russian Federation;Israel;Italy;United Kingdom;France;Czech Republic;Hungary;Canada;Denmark;Germany | |||
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 36 | JPRN-UMIN000036952 | 2019/06/04 | 04/06/2019 | A PET study with 18F-FDOPA and 11C-Raclopride on Parkinson's disease and related disorders patients. | A PET study with 18F-FDOPA and 11C-Raclopride on Parkinson's disease and related disorders patients. - A PET study with 18F-FDOPA and 11C-Raclopride on Parkinson's disease and related disorders patients. | Patients who are suspected Parkinson's disease or related disorders, including dementia with Lewy bodies, multiple system atrophy, progressive supranuclear palsy, corticobasal degeneration, frontotemporal lobe degeneration, vascular parkinsonism, drug-induced parkinsonism, normal pressure hydrocephalus, and others. | 18F-FDOPA, 11C-Raclopride PET | Nagoya City Rehabilitation Agency | NULL | Recruiting | 20years-old | Not applicable | Male and Female | 150 | Not applicable | Japan |
| 37 | EUCTR2018-003289-15-HU (EUCTR) | 04/06/2019 | 05/04/2019 | This study will look at whether an investigational drug called TD-9855 works and how safe it is for treating symptomatic neurogenic orthostatic hypotension (snOH) in people with Parkinson’s disease (PD), multiple system atrophy (MSA) or pure autonomic failure (PAF) | A Phase 3, 4-week, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study of TD-9855 in Treating Symptomatic Neurogenic Orthostatic Hypotension in Subjects With Primary Autonomic Failure - Phase 3 Clinical Effect of TD-9855 for Treating snOH in Subjects With Primary Autonomic Failure | Symptomatic Neurogenic Orthostatic Hypotension in Subjects with Primary Autonomic Failure;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Theravance Biopharma Ireland Limited | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 188 | Phase 3 | United States;Estonia;Spain;Ukraine;Austria;Russian Federation;Israel;Italy;United Kingdom;France;Hungary;Czech Republic;Canada;Denmark;Germany | |||
| 38 | EUCTR2018-003289-15-AT (EUCTR) | 15/05/2019 | 22/03/2019 | This study will look at whether an investigational drug called TD-9855 works and how safe it is for treating symptomatic neurogenic orthostatic hypotension (snOH) in people with Parkinson’s disease (PD), multiple system atrophy (MSA) or pure autonomic failure (PAF) | A Phase 3, 4-week, Multicenter, Randomized, Double-blind,Placebo-controlled, Parallel-group Study of TD-9855 inTreating Symptomatic Neurogenic Orthostatic Hypotension inSubjects With Primary Autonomic Failure - Sequoia study | Symptomatic Neurogenic Orthostatic Hypotension in Subjects with Primary Autonomic Failure;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Code: TD-9855 INN or Proposed INN: ampreloxetine hydrochloride Other descriptive name: TD-9855 | Theravance Biopharma Ireland Limited | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 188 | Phase 3 | United States;Portugal;Czechia;Estonia;Spain;Ukraine;Austria;Russian Federation;Chile;Israel;United Kingdom;Italy;France;Hungary;Mexico;Canada;Argentina;Poland;Peru;Australia;Denmark;Bulgaria;Germany;New Zealand | ||
| 39 | EUCTR2018-003289-15-GB (EUCTR) | 08/05/2019 | 28/12/2018 | This study will look at whether an investigational drug called TD-9855 works and how safe it is for treating symptomatic neurogenic orthostatic hypotension (snOH) in people with Parkinson’s disease (PD), multiple system atrophy (MSA) or pure autonomic failure (PAF) | A Phase 3, 4-week, Multicenter, Randomized, Double-blind,Placebo-controlled,Parallel-group Study of TD-9855 in Treating Symptomatic Neurogenic Orthostatic Hypotension in Subjects With Primary Autonomic Failure - Sequoia study | Symptomatic Neurogenic Orthostatic Hypotension in Subjects with Primary Autonomic Failure;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Code: TD-9855 INN or Proposed INN: ampreloxetine hydrochloride Other descriptive name: TD-9855 | Theravance Biopharma Ireland Limited | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 188 | Phase 3 | United States;Portugal;Estonia;Spain;Ukraine;Austria;Russian Federation;Chile;Israel;Italy;United Kingdom;France;Hungary;Mexico;Canada;Argentina;Poland;Peru;Australia;Denmark;Bulgaria;Germany;New Zealand | ||
| 40 | EUCTR2018-003289-15-EE (EUCTR) | 11/04/2019 | 30/01/2019 | This study will look at whether an investigational drug called TD-9855 works and how safe it is for treating symptomatic neurogenic orthostatic hypotension (snOH) in people with Parkinson’s disease (PD), multiple system atrophy (MSA) or pure autonomic failure (PAF) | A Phase 3, 4-week, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study of TD-9855 in Treating Symptomatic Neurogenic Orthostatic Hypotension in Subjects With Primary Autonomic Failure - Phase 3 Clinical Effect of TD-9855 for Treating snOH in Subjects With Primary Autonomic Failure | Symptomatic Neurogenic Orthostatic Hypotension in Subjects with Primary Autonomic Failure;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Theravance Biopharma Ireland Limited | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 188 | Phase 3 | United States;Estonia;Spain;Ukraine;Austria;Russian Federation;Israel;Italy;United Kingdom;France;Hungary;Canada;Poland;Australia;Denmark;Bulgaria;Germany;New Zealand | |||
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 41 | NCT03901638 (ClinicalTrials.gov) | April 2, 2019 | 24/3/2019 | Tllsh2910 for Ataxia and Gut Microbiota Alteration in Patients of Multiple System Atrophy | Gut Microbiota Alteration and Improvement of Ataxia in Patients of Multiple System Atrophy Treating With Tllsh2910 - a Randomized, Placebo-controlled, Double-blinded, Cross-over, Single-center Clinical Trial | Ataxia, Cerebellar;Multiple System Atrophy | Drug: Tllsh2910;Drug: Placebo | National Taiwan University Hospital | NULL | Recruiting | 18 Years | 80 Years | All | 60 | Phase 3 | Taiwan |
| 42 | EUCTR2018-000506-34-SI (EUCTR) | 04/02/2019 | 09/03/2018 | EMERA006 - A pilot, exploratory, randomised, placebo-controlled, double blinded, cross-over, Phase 2a study to explore efficacy and safety of NBMI treatment in patients with Progressive Supranuclear Palsy (PSP) or Multiple System Atrophy (MSA). | EMERA006- A pilot, exploratory, randomised, placebo-controlled, double blinded, cross-over, Phase 2a study to explore efficacy and safety of NBMI treatment in patients with Progressive Supranuclear Palsy (PSP) or Multiple System Atrophy (MSA). - EMERA006 | PSP or MSA;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | NBMI Science Ltd. | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 20 | Phase 2 | Slovenia | |||
| 43 | NCT03648905 (ClinicalTrials.gov) | September 6, 2018 | 24/8/2018 | Clinical Laboratory Evaluation of Chronic Autonomic Failure | Clinical Laboratory Evaluation of Chronic Autonomic Failure | Parkinson's Disease;Multiple System Atrophy;Autonomic Failure | Drug: 18F-Dopa;Drug: 11C-methylreboxetine;Drug: 13N-Ammonia;Drug: 18F-Dopamne;Drug: Desipramine (DMI) | National Institute of Neurological Disorders and Stroke (NINDS) | NULL | Recruiting | 18 Years | N/A | All | 140 | Phase 1 | United States |
| 44 | NCT03589976 (ClinicalTrials.gov) | September 1, 2018 | 5/7/2018 | A Futility Trial of Sirolimus in Multiple System Atrophy | A Single Center Randomized,Double Blind, Placebo-controlled Futility Trial to Determine if Sirolimus is of Sufficient Promise to Slow the Progression of Multiple System Atrophy | Multiple System Atrophy | Drug: Sirolimus 2 MG;Other: Placebo | NYU Langone Health | National Institute of Neurological Disorders and Stroke (NINDS) | Recruiting | 30 Years | 80 Years | All | 56 | Phase 2 | United States |
| 45 | NCT03403309 (ClinicalTrials.gov) | May 2, 2018 | 11/1/2018 | Inosine 5'-Monophosphate to Raise of Serum Uric Acid Level in Patients With Multiple System Atrophy: a Multi-center, Randomized Controlled, Double Blind, Parallel Assigned Clinical Trial | Inosine 5'-Monophosphate to Raise of Serum Uric Acid Level in Patients With Multiple System Atrophy: a Multi-center, Randomized Controlled, Double Blind, Parallel Assigned Clinical Trial (IMPROVE MSA Study) | Multiple System Atrophy | Drug: 1) Inosine 5'-monophosphate;Drug: Placebo | Yonsei University | NULL | Completed | 19 Years | 75 Years | All | 43 | Phase 2 | Korea, Republic of |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 46 | NCT03265444 (ClinicalTrials.gov) | April 13, 2018 | 6/8/2017 | Safety and Tolerability of CS10BR05 Inj. in Subjects With Multiple System Atrophy | A Phase 1 Study to Evaluate the Safety and Tolerability of Autologous Bone Marrow Derived Mesenchymal Stem Cells in Subjects With Multiple System Atrophy | Multiple System Atrophy | Biological: CS10BR05 | Corestem, Inc. | NULL | Completed | 30 Years | 75 Years | All | 9 | Phase 1 | Korea, Republic of |
| 47 | NCT03408080 (ClinicalTrials.gov) | December 15, 2017 | 17/1/2018 | An Open Pilot Trial of BHV-4157 | An Open Pilot Trial of BHV-4157 in Adult Subjects With Cerebellar Ataxia | Spinocerebellar Ataxias;Spinocerebellar Ataxia Type 1;Spinocerebellar Ataxia Type 2;Spinocerebellar Ataxia 3;Spinocerebellar Ataxia Type 6;MSA-C | Drug: BHV-4157 | University of California, Los Angeles | NULL | Active, not recruiting | 18 Years | 75 Years | All | 24 | Phase 3 | United States |
| 48 | NCT03174938 (ClinicalTrials.gov) | May 15, 2017 | 28/5/2017 | The Swedish BioFINDER 2 Study | The Swedish BioFINDER 2 Study | Dementia;Alzheimer Disease;Parkinson Disease;Lewy Body Disease;Parkinson-Dementia Syndrome;Frontotemporal Degeneration;Semantic Dementia;Progressive Nonfluent Aphasia;Progressive Supranuclear Palsy;Corticobasal Degeneration;Multiple System Atrophy;Mild Cognitive Impairment | Diagnostic Test: Flutemetamol F18 Injection;Diagnostic Test: [18F]-RO6958948;Diagnostic Test: Elecsys (Roche) Abeta42, Ttau and Ptau;Diagnostic Test: Lumipulse (Fujirebio) Abeta42, Ttau and Ptau | Skane University Hospital | Lund University | Recruiting | 20 Years | 100 Years | All | 1505 | N/A | Sweden |
| 49 | NCT02897063 (ClinicalTrials.gov) | September 2016 | 7/9/2016 | Effects of Midodrine and Droxidopa on Splanchnic Capacitance in Autonomic Failure | The Effects of Midodrine and Droxidopa on Splanchnic Capacitance in Autonomic Failure Aim 2 of RDCRN (Rare Diseases Clinical Research Network) Project 2 | Autonomic Failure;Pure Autonomic Failure;Multiple System Atrophy;Parkinson Disease;Orthostatic Hypotension | Drug: Droxidopa;Drug: Midodrine;Drug: Placebo | Vanderbilt University Medical Center | NULL | Recruiting | 40 Years | 80 Years | All | 34 | Phase 1 | United States |
| 50 | NCT02705755 (ClinicalTrials.gov) | May 2016 | 7/3/2016 | TD-9855 Phase 2 in Neurogenic Orthostatic Hypotension (nOH) | A Phase 2 Study to Assess the Effect of TD-9855 in Subjects With Neurogenic Orthostatic Hypotension | Neurogenic Orthostatic Hypotension;Multiple System Atrophy (MSA) With Orthostatic Hypotension;Pure Autonomic Failure;Parkinson Disease;Hypotension, Orthostatic;Orthostatic Hypotension;Pure Autonomic Failure With Orthostatic Hypotension;Parkinson Disease With Orthostatic Hypotension | Drug: TD-9855;Drug: Placebo | Theravance Biopharma | NULL | Completed | 40 Years | N/A | All | 34 | Phase 2 | United States |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 51 | NCT02796209 (ClinicalTrials.gov) | May 2016 | 7/6/2016 | Norepinephrine Transporter Blockade, Autonomic Failure | Phase 2 Norepinephrine Transporter Blockade, Autonomic Failure | Multiple System Atrophy (MSA) | Drug: Atomexetine;Drug: Placebo | NYU Langone Health | Vanderbilt University Medical Center | Recruiting | 40 Years | 80 Years | All | 40 | Phase 2 | United States |
| 52 | NCT02726711 (ClinicalTrials.gov) | April 2016 | 28/1/2016 | Reduction in Splanchnic Capacitance Contributes to Sympathetically Dependent Hypertension in Autonomic | Reduction in Splanchnic Capacitance Contributes to Sympathetically Dependent Hypertension in Autonomic Aim 1 of Rare Diseases Clinical Research Network (RDCRN) Project 2 | Multiple System Atrophy;Orthostatic Hypotension;Supine Hypertension | Drug: Trimethaphan;Drug: Placebo | Vanderbilt University | NULL | Active, not recruiting | 40 Years | 80 Years | All | 2 | Phase 1 | United States |
| 53 | NCT02994719 (ClinicalTrials.gov) | March 1, 2016 | 21/12/2015 | Gait Analysis in Neurological Disease | Gait Pattern Analysis in Neurological Disease | Parkinson's Disease;Parkinsonian Disorders;Atypical Parkinson Disease;Progressive Supranuclear Palsy;Multiple System Atrophy;Corticobasal Degeneration;Gait, Frontal;Huntington Disease | Drug: Anti-Parkinson medication;Device: Deep Brain Stimulation | Beth Israel Deaconess Medical Center | NULL | Active, not recruiting | 18 Years | 85 Years | All | 120 | United States | |
| 54 | NCT02591173 (ClinicalTrials.gov) | February 2016 | 27/10/2015 | Blood Pressure Lowering Effects of Angiotensin-(1-7) in Primary Autonomic Failure | Blood Pressure Lowering Effects of Angiotensin-(1-7) in Primary Autonomic Failure | Autonomic Nervous System Disorders;Pure Autonomic Failure;Shy-Drager Syndrome;Orthostatic Hypotension, Dysautonomic | Drug: Angiotensin-(1-7);Drug: Saline | Vanderbilt University Medical Center | NULL | Recruiting | 18 Years | 80 Years | All | 22 | Early Phase 1 | United States |
| 55 | NCT02388295 (ClinicalTrials.gov) | April 27, 2015 | 9/3/2015 | AZD3241 PET MSA Trial, Phase 2, Randomized,12 Week Safety and Tolerability Trial With PET in MSA Patients | A 12-Week, Multicenter, Randomized, Parallel-Group Study to Assess the Safety, Tolerability, Pharmacokinetics, Biomarker Effects, Efficacy, and Effect on Microglia Activation, as Measured by Positron Emission Tomography, of AZD3241 in Subjects With Multiple System Atrophy | Multiple System Atrophy, MSA | Drug: AZD3241;Drug: Placebo | AstraZeneca | NULL | Completed | 30 Years | 80 Years | All | 59 | Phase 2 | United States;Austria;Finland;France;Italy;Sweden;United Kingdom |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 56 | EUCTR2014-004902-13-SE (EUCTR) | 14/04/2015 | 02/01/2015 | Study to assess the effect of AZD3241 in Multiple System Atrophy | A 12-Week, Multicenter, Randomized, Parallel-Group Study to Assess the Safety, Tolerability, Pharmacokinetics, Biomarker Effects, Efficacy, and Effect on Microglia Activation, as Measured by Positron Emission Tomography, of AZD3241 in Subjects with Multiple System Atrophy | Multiple system atrophy (MSA) MedDRA version: 18.1;Level: PT;Classification code 10064060;Term: Multiple system atrophy;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: AZD3241 100mg Product Code: AZD3241 INN or Proposed INN: Not available Other descriptive name: IUPAC name: 1-(2-Isopropoxyethyl)-2-thioxo-1,2,3,5-tetrahydro-pyrrolo[3,2-d] pyrimidin-4-one Product Name: AZD3241 300mg Product Code: AZD3241 INN or Proposed INN: Not available Other descriptive name: 1-(2-Isopropoxyethyl)-2-thioxo-1,2,3,5-tetrahydro-pyrrolo[3,2-d] pyrimidin-4-one | AstraZeneca AB | NULL | Not Recruiting | Female: yes Male: yes | 64 | Phase 2 | France;United States;Finland;Austria;Italy;United Kingdom;Sweden | ||
| 57 | EUCTR2014-004902-13-GB (EUCTR) | 09/04/2015 | 24/12/2014 | Study to assess the effect of AZD3241 in Multiple System Atrophy | A 12-Week, Multicenter, Randomized, Parallel-Group Study to Assess the Safety, Tolerability, Pharmacokinetics, Biomarker Effects, Efficacy, and Effect on Microglia Activation, as Measured by Positron Emission Tomography, of AZD3241 in Subjects with Multiple System Atrophy | Multiple system atrophy (MSA) MedDRA version: 18.1;Level: PT;Classification code 10064060;Term: Multiple system atrophy;System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | AstraZeneca AB | NULL | Not Recruiting | Female: yes Male: yes | 64 | Phase 2 | United States;Finland;United Kingdom;Sweden | |||
| 58 | NCT02429557 (ClinicalTrials.gov) | April 2015 | 21/4/2015 | Hemodynamic Mechanisms of Abdominal Compression in the Treatment of Orthostatic Hypotension in Autonomic Failure | Hemodynamic Mechanisms of Abdominal Compression in the Treatment of Orthostatic Hypotension in Autonomic Failure | Orthostatic Hypotension;Pure Autonomic Failure;Multiple System Atrophy;Autonomic Failure | Other: Abdominal compression;Other: Sham abdominal compression;Drug: Placebo pill;Drug: midodrine | Vanderbilt University | NULL | Recruiting | 18 Years | 80 Years | All | 20 | Phase 1 | United States |
| 59 | ChiCTR-DPC-15005941 | 2015-03-01 | 2015-01-25 | Study for the diagnosis and differential diagnosis of multiple system atrophy | Study for the diagnosis and differential diagnosis of multiple system atrophy | Multiple system atrophy | Gold Standard:electrophysiological techniques;Index test:brain MRI; | Navy general hospital | NULL | Completed | 30 | 80 | Both | Target condition:260;Difficult condition:0 | China | |
| 60 | EUCTR2014-004902-13-FI (EUCTR) | 11/02/2015 | 31/12/2014 | Study to assess the effect of AZD3241 in Multiple System Atrophy | A 12-Week, Multicenter, Randomized, Parallel-Group Study to Assess the Safety, Tolerability, Pharmacokinetics, Biomarker Effects, Efficacy, and Effect on Microglia Activation, as Measured by Positron Emission Tomography, of AZD3241 in Subjects with Multiple System Atrophy | Multiple system atrophy (MSA) MedDRA version: 18.1;Level: PT;Classification code 10064060;Term: Multiple system atrophy;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: AZD3241 100mg Product Code: AZD3241 INN or Proposed INN: Not available Other descriptive name: IUPAC name: 1-(2-Isopropoxyethyl)-2-thioxo-1,2,3,5-tetrahydro-pyrrolo[3,2-d] pyrimidin-4-one Product Name: AZD3241 300mg Product Code: AZD3241 INN or Proposed INN: Not available Other descriptive name: 1-(2-Isopropoxyethyl)-2-thioxo-1,2,3,5-tetrahydro-pyrrolo[3,2-d] pyrimidin-4-one | AstraZeneca AB | NULL | Not Recruiting | Female: yes Male: yes | 64 | Phase 2 | United States;France;Finland;Austria;United Kingdom;Italy;Sweden | ||
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 61 | NCT02270489 (ClinicalTrials.gov) | December 11, 2014 | 4/9/2014 | Study Assessing Safety and Therapeutic Activity of AFFITOPE® PD01A and PD03A in Patients With Early MSA | A Randomized, Placebo-controlled, Parallel Group, Patient-blind, Phase I Study Assessing the Safety and Exploring the Immunogenicity/Therapeutic Activity of AFFITOPE® PD01A and PD03A in Patients With Early Multiple System Atrophy | Multiple System Atrophy;Neurodegenerative Diseases | Biological: AFFITOPE® PD01A + Adjuvant;Biological: AFFITOPE® PD03A + Adjuvant;Biological: Adjuvant without active component | Affiris AG | University Hospital, Bordeaux;Institut National de la Santé Et de la Recherche Médicale, France;Forschungszentrum Juelich;University Hospital, Toulouse | Completed | 30 Years | 75 Years | All | 30 | Phase 1 | France |
| 62 | NCT02149901 (ClinicalTrials.gov) | October 2014 | 26/5/2014 | Water and Sudafed in Autonomic Failure | Effect of Drinking Water on the Pressor Response to Pseudoephedrine in Patients With Autonomic Failure | Shy-Drager Syndrome;Multiple System Atrophy | Drug: Pseudoephedrine + 480 ml water;Drug: Pseudoephedrine + 50 ml water;Other: Placebo + 480 ml water (optional);Other: Placebo + 50 ml water (optional) | Vanderbilt University | National Heart, Lung, and Blood Institute (NHLBI);National Center for Advancing Translational Science (NCATS) | Active, not recruiting | 18 Years | 80 Years | All | 35 | Early Phase 1 | United States |
| 63 | EUCTR2012-005539-10-DE (EUCTR) | 29/04/2014 | 18/12/2013 | Clinical study to investigate the efficacy and safety of two dose levels of NT 201 versus placebo in treating chronic troublesome sialorrhea in various neurological conditions. | Prospective, randomized, double-blind, placebo-controlled, parallel-group multicenter study, with an extension period of dose-blinded active treatment, to investigate the efficacy and safety of two dose levels of NT 201 in treating chronic troublesome sialorrhea in various neurological conditions - SIAXI – Sialorrhea in Adults Xeomin Investigation | Chronic troublesome sialorrhea resulting from neurological conditions in adults with Parkinson's disease or atypical parkinsonism (multiple system atrophy, corticobasal degeneration or progressive supranuclear palsy), or after stroke or traumatic brain injury. MedDRA version: 18.1;Level: PT;Classification code 10039424;Term: Salivary hypersecretion;System Organ Class: 10017947 - Gastrointestinal disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Trade Name: Xeomin INN or Proposed INN: NT 101 Other descriptive name: BOTULINUM TOXIN TYPE A Trade Name: Xeomin INN or Proposed INN: NT 101 Other descriptive name: BOTULINUM TOXIN TYPE A | Merz Pharmaceuticals GmbH | NULL | Not Recruiting | Female: yes Male: yes | 180 | Phase 3 | United States;Poland;Germany | ||
| 64 | NCT02064166 (ClinicalTrials.gov) | February 2014 | 13/2/2014 | Treatment of Parkinson Disease and Multiple System Atrophy Using Intranasal Insulin. | A Double-blinded Placebo-controlled Single-center Study to Evaluate the Efficacy of Intranasal Insulin 40 International Units Day as Treatment for Subjects With Parkinson Disease and Multiple System Atrophy | Parkinson Disease;Multiple System Atrophy | Drug: Intranasal Insulin | Peter Novak | NULL | Completed | 18 Years | N/A | All | 15 | Phase 2 | United States |
| 65 | NCT02071459 (ClinicalTrials.gov) | January 21, 2014 | 21/2/2014 | Efficacy of L-threo DOPS on Orthostatic Hypotension Symptoms and Other Non-motor Symptoms in Patients With MSA | Evaluate the Long-term (3 Months) Efficacy of L-threo DOPS (DroxiDopa) on Orthostatic Hypotension Symptoms and Other Non-motor Symptoms in Patients With Multiple System Atrophy (MSA). Comparative Study Versus Placebo | Multiple System Atrophy | Drug: L-Threo DOPS;Drug: placebo | University Hospital, Toulouse | NULL | Completed | 30 Years | 80 Years | All | 107 | Phase 2;Phase 3 | France |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 66 | NCT02008721 (ClinicalTrials.gov) | January 2014 | 8/12/2013 | Progression Rate of MSA Under EGCG Supplementation as Anti-Aggregation-Approach | Double-blind, Randomised, Placebo-controlled Parallel Group Study to Investigate the Effect of EGCG Supplementation on Disease Progression of Patients With Multiple System Atrophy (MSA) | Multiple System Atrophy | Drug: EGCG as putative neuroprotective agent;Drug: Placebo | Dr. Johannes Levin | German Center for Neurodegenerative Diseases (DZNE);Deutsche Parkinson Vereinigung;Deutsche Stiftung Neurologie;ParkinsonFonds Deutschland gGmbH | Completed | 18 Years | N/A | Both | 92 | Phase 3 | Germany |
| 67 | EUCTR2012-000928-18-DE (EUCTR) | 21/11/2013 | 28/06/2013 | Double blind, randomised, prospective placebo controlled parallel group phase III study to investigate the Effect of EGCG supplementation on disease progression of patients with Multiple System Atrophy (MSA) | Double blind, randomised, prospective placebo controlled parallel group phase III study to investigate the Effect of EGCG supplementation on disease progression of patients with Multiple System Atrophy (MSA) - Progression Rate of MSA under EGCG Supplementation as anti-Aggregation-Approach | Progression of patients with Multiple System Atrophy (MSA);Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Trade Name: Sunphenon EGCg INN or Proposed INN: EGCG Other descriptive name: GREEN TEA LEAF | Hospital of the Ludwig-Maximilians-University of Munich | NULL | Not Recruiting | Female: yes Male: yes | 86 | Phase 3 | Germany | ||
| 68 | JPRN-UMIN000011111 | 2013/07/16 | 15/07/2013 | Spinal blood flow and metabolism in neurological diseases | motor neuron disease including ALS, multiple sclerosis, stroke, Parkinson disease, spinocerebellar degeneration, multiple system atrophy | PET scan study with 11C-flumazenil PET scan study with 18F- FDG PET scan study with 15O-H2O | Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences | NULL | Recruiting | 20years-old | Not applicable | Male and Female | 70 | Not applicable | Japan | |
| 69 | JPRN-UMIN000010712 | 2013/05/20 | 15/05/2013 | Ubiquinol for patients with multiple system atrophy | Patients with multiple system atrophy | Patients with administration of ubiquinol | Department of Neurology, the University of Tokyo Hospital | NULL | Complete: follow-up complete | 30years-old | 80years-old | Male and Female | 1 | Not selected | Japan | |
| 70 | JPRN-UMIN000008959 | 2012/11/01 | 16/10/2012 | Trial of molecular hydrogen water in Multiple system atrophy and Progressive supranuclear palsy | Multiple system atrophy(MSA)Progressive supranuclear palsy (PSP) | hydrogen water pseudo-water (nitrogen filling water) | Juntendo University School of Medicine, Department of Neurology | NULL | Complete: follow-up complete | 20years-old | 80years-old | Male and Female | 40 | Phase 1 | Japan | |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 71 | NCT02315027 (ClinicalTrials.gov) | October 2012 | 31/10/2014 | Mesenchymal Stem Cell Therapy in Multiple System Atrophy | Intrathecal Autologous Mesenchymal Stem Cell Therapy in Multiple System Atrophy (MSA) - Effect of Dose and Natural History | MSA | Biological: autologous mesenchymal stem cells | Mayo Clinic | NULL | Active, not recruiting | 30 Years | 80 Years | All | 30 | Phase 1 | United States |
| 72 | NCT01577992 (ClinicalTrials.gov) | December 2011 | 7/11/2011 | Evaluation of the Subjective and Objective Painful Threshold in Multiple System Atrophy Pain and Multiple System Atrophy | Evaluation of the Subjective and Objective Painful Threshold in Multiple System Atrophy Pain and Multiple System Atrophy | Pain Threshold;Multiple System Atrophy | Drug: Levodopa test;Procedure: determination of objective and subjective pain threshold | University Hospital, Toulouse | Fondation de France | Completed | 50 Years | 80 Years | Both | 42 | N/A | France |
| 73 | NCT01292694 (ClinicalTrials.gov) | March 2011 | 8/2/2011 | Contribution of Angiotensin II to Supine Hypertension in Autonomic Failure | Contribution of Angiotensin II to Supine Hypertension in Autonomic Failure | Hypertension;Pure Autonomic Failure;Multiple System Atrophy | Drug: Losartan;Drug: Captopril;Drug: Placebo | Vanderbilt University | NULL | Terminated | 18 Years | 85 Years | All | 12 | Phase 1 | United States |
| 74 | NCT01287221 (ClinicalTrials.gov) | March 2011 | 28/1/2011 | Study of Rifampicin in Multiple System Atrophy | Double-Blind, Placebo-Controlled Study of Rifampicin in Multiple System Atrophy | Multiple System Atrophy | Drug: Rifampicin;Drug: placebo | Phillip Low | National Institute of Neurological Disorders and Stroke (NINDS);Vanderbilt University;Rare Disease Research Network Autonomic Consortium | Terminated | 30 Years | 80 Years | All | 100 | Phase 3 | United States |
| 75 | EUCTR2009-018157-23-GB (EUCTR) | 30/11/2010 | 16/06/2010 | A Phase IIa, Multi-Centre, Double-Blind, Randomised, Placebo-Controlled, Parallel Group 12-Month Treatment, Adaptive Design Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of AZD3241 in Patients with Multiple System Atrophy | A Phase IIa, Multi-Centre, Double-Blind, Randomised, Placebo-Controlled, Parallel Group 12-Month Treatment, Adaptive Design Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of AZD3241 in Patients with Multiple System Atrophy | Multiple system atrophy MedDRA version: 12.1;Level: LLT;Classification code 10064060;Term: Multiple system atrophy | Product Name: AZD3241 Product Code: AZD3241 Product Name: AZD3241 Product Code: AZD3241 | AstraZeneca AB | NULL | Not Recruiting | Female: yes Male: yes | 135 | Phase 2a | United Kingdom;Spain;Austria | ||
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 76 | EUCTR2009-018157-23-AT (EUCTR) | 11/11/2010 | 07/07/2010 | A Phase IIa, Multi-Centre, Double-Blind, Randomised, Placebo-Controlled, Parallel Group, 12-Month Treatment, Adaptive Design Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of AZD3241 in Patients with Multiple System Atrophy | A Phase IIa, Multi-Centre, Double-Blind, Randomised, Placebo-Controlled, Parallel Group, 12-Month Treatment, Adaptive Design Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of AZD3241 in Patients with Multiple System Atrophy | Multiple system atrophy MedDRA version: 12.1;Level: LLT;Classification code 10064060;Term: Multiple system atrophy | Product Name: AZD3241 Product Code: AZD3241 Product Name: AZD3241 Product Code: AZD3241 | AstraZeneca AB | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 120 | Phase 2a | United Kingdom;Spain;Austria | ||
| 77 | EUCTR2009-018157-23-ES (EUCTR) | 14/09/2010 | 23/06/2010 | A Phase IIa, Multi-Centre, Double-Blind, Randomised, Placebo-Controlled, Parallel Group 12-Month Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of AZD3241 in Patients with Multiple System AtrophyEstudio de fase IIa, multicéntrico, doble ciego, aleatorizado, controlado con placebo, de gruposparalelos, de 12 meses de duración para evaluar la eficacia, la seguridad, la tolerabilidad y lafarmacocinética de AZD3241 en pacientes con atrofia multisistémica | A Phase IIa, Multi-Centre, Double-Blind, Randomised, Placebo-Controlled, Parallel Group 12-Month Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of AZD3241 in Patients with Multiple System AtrophyEstudio de fase IIa, multicéntrico, doble ciego, aleatorizado, controlado con placebo, de gruposparalelos, de 12 meses de duración para evaluar la eficacia, la seguridad, la tolerabilidad y lafarmacocinética de AZD3241 en pacientes con atrofia multisistémica | Multiple system atrophyAtrofia Multisistémica MedDRA version: 12.1;Level: LLT;Classification code 10064060;Term: Multiple system atrophy | Product Name: AZD3241 Product Code: AZD3241 Product Name: AZD3241 Product Code: AZD3241 | AstraZeneca AB | NULL | Not Recruiting | Female: yes Male: yes | 110 | Phase 2a | United Kingdom;Spain;Austria | ||
| 78 | NCT01119417 (ClinicalTrials.gov) | May 2010 | 4/5/2010 | The Role of Endothelin in the Supine Hypertension of Autonomic Failure | The Role of Endothelin in the Supine Hypertension of Autonomic Failure | Hypertension;Pure Autonomic Failure;Multiple System Atrophy | Drug: BQ123;Drug: Bq123;Drug: Saline | Vanderbilt University | NULL | Enrolling by invitation | 18 Years | 85 Years | All | 12 | Phase 1 | United States |
| 79 | NCT01136213 (ClinicalTrials.gov) | April 2010 | 26/5/2010 | Investigation of the Serotoninergic System in Multiple System Atrophy: a Positron Emission Tomography (PET) Study | Morphological and Functional Investigation of the Serotoninergic System in Multiple System Atrophy: a 18F-MPPF PET Study | Multiple System Atrophy | Radiation: PET (Positron Emission Tomography) Study;Other: Brain MRI (magnetic resonance imaging);Drug: Fluoxétine / Placebo | University Hospital, Bordeaux | NULL | Completed | 30 Years | 80 Years | All | 53 | N/A | France |
| 80 | EUCTR2009-014644-11-AT (EUCTR) | 10/03/2010 | 21/10/2009 | A Multi-centered, Randomized, Double-blind, Placebo-controlled Clinical Trial to Assess the Efficacy, Safety, and Tolerability of Rasagiline Mesylate 1 mg in Patients with Multiple System Atrophy of the Parkinsonian Subtype (MSA-P) | A Multi-centered, Randomized, Double-blind, Placebo-controlled Clinical Trial to Assess the Efficacy, Safety, and Tolerability of Rasagiline Mesylate 1 mg in Patients with Multiple System Atrophy of the Parkinsonian Subtype (MSA-P) | Multiple System Atrophy of the Parkinsonian Subtype MedDRA version: 12.0;Level: PT;Classification code 10064060;Term: Multiple system atrophy | Trade Name: AZILECT INN or Proposed INN: Rasagiline Other descriptive name: Rasagiline mesylate | Teva Pharmaceutical Industries Ltd | NULL | Not Recruiting | Female: yes Male: yes | 140 | Portugal;Hungary;United Kingdom;Germany;Netherlands;France;Spain;Italy;Austria | |||
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 81 | EUCTR2009-014644-11-NL (EUCTR) | 11/02/2010 | 29/10/2009 | A Multi-centered, Randomized, Double-blind, Placebo-controlled Clinical Trial to Assess the Efficacy, Safety, and Tolerability of Rasagiline Mesylate 1 mg in Patients with Multiple System Atrophy of the Parkinsonian Subtype (MSA-P) | A Multi-centered, Randomized, Double-blind, Placebo-controlled Clinical Trial to Assess the Efficacy, Safety, and Tolerability of Rasagiline Mesylate 1 mg in Patients with Multiple System Atrophy of the Parkinsonian Subtype (MSA-P) | Multiple System Atrophy of the Parkinsonian Subtype MedDRA version: 12.0;Level: PT;Classification code 10064060;Term: Multiple system atrophy | Trade Name: AZILECT INN or Proposed INN: Rasagiline Other descriptive name: Rasagiline mesylate | Teva Pharmaceutical Industries Ltd | NULL | Not Recruiting | Female: yes Male: yes | 243 | Portugal;Hungary;United Kingdom;Germany;Netherlands;France;Spain;Italy;Austria | |||
| 82 | EUCTR2009-014644-11-PT (EUCTR) | 05/02/2010 | 11/01/2010 | A Multi-centered, Randomized, Double-blind, Placebo-controlled Clinical Trial to Assess the Efficacy, Safety, and Tolerability of Rasagiline Mesylate 1 mg in Patients with Multiple System Atrophy of the Parkinsonian Subtype (MSA-P) | A Multi-centered, Randomized, Double-blind, Placebo-controlled Clinical Trial to Assess the Efficacy, Safety, and Tolerability of Rasagiline Mesylate 1 mg in Patients with Multiple System Atrophy of the Parkinsonian Subtype (MSA-P) | Multiple System Atrophy of the Parkinsonian Subtype MedDRA version: 12.0;Level: PT;Classification code 10064060;Term: Multiple system atrophy | Trade Name: AZILECT INN or Proposed INN: Rasagiline Other descriptive name: Rasagiline mesylate | Teva Pharmaceutical Industries Ltd | NULL | Not Recruiting | Female: yes Male: yes | 140 | Hungary;Portugal;United Kingdom;Germany;Netherlands;France;Spain;Italy;Austria | |||
| 83 | EUCTR2009-014644-11-GB (EUCTR) | 25/01/2010 | 04/08/2010 | A Multi-centered, Randomized, Double-blind, Placebo-controlled Clinical Trial to Assess the Efficacy, Safety, and Tolerability of Rasagiline Mesylate 1 mg in Patients with Multiple System Atrophy of the Parkinsonian Subtype (MSA-P) | A Multi-centered, Randomized, Double-blind, Placebo-controlled Clinical Trial to Assess the Efficacy, Safety, and Tolerability of Rasagiline Mesylate 1 mg in Patients with Multiple System Atrophy of the Parkinsonian Subtype (MSA-P) | Multiple System Atrophy of the Parkinsonian Subtype MedDRA version: 12.0;Level: PT;Classification code 10064060;Term: Multiple system atrophy | Teva Pharmaceutical Industries Ltd | NULL | Not Recruiting | Female: yes Male: yes | 140 | Phase 2 | Portugal;France;Hungary;Spain;Austria;Netherlands;Germany;Italy;United Kingdom | |||
| 84 | NCT01044693 (ClinicalTrials.gov) | January 2010 | 6/1/2010 | Nebivolol in the Supine Hypertension of Autonomic Failure | Effect of Nebivolol on Blood Pressure in a Model of Hypertension Sensitive to Potentiation of Nitric Oxide Bioactivity | Hypertension;Pure Autonomic Failure;Multiple System Atrophy | Drug: Placebo;Drug: Nebivolol 5 mg;Drug: metoprolol tartrate 50 mg;Drug: Sildenafil25 mg | Vanderbilt University | Forest Laboratories | Completed | 18 Years | 80 Years | All | 20 | N/A | United States |
| 85 | EUCTR2009-014644-11-IT (EUCTR) | 10/12/2009 | 22/12/2009 | A Multi-centered, Randomized, Double-blind, Placebo-controlled Clinical Trial to Assess the Efficacy, Safety, and Tolerability of Rasagiline Mesylate 1 mg in Patients with Multiple System Atrophy of the Parkinsonian Subtype (MSA-P) - ND | A Multi-centered, Randomized, Double-blind, Placebo-controlled Clinical Trial to Assess the Efficacy, Safety, and Tolerability of Rasagiline Mesylate 1 mg in Patients with Multiple System Atrophy of the Parkinsonian Subtype (MSA-P) - ND | Multiple System Atrophy of the Parkinsonian subtype (MSA-P) MedDRA version: 12.1;Level: LLT;Classification code 10064060;Term: Multiple system atrophy | Trade Name: AZILECT INN or Proposed INN: Rasagiline | Teva Pharmaceutical Industries Ltd | NULL | Not Recruiting | Female: yes Male: yes | 140 | Portugal;Hungary;United Kingdom;Germany;Netherlands;France;Spain;Italy;Austria | |||
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 86 | EUCTR2009-014644-11-DE (EUCTR) | 08/12/2009 | 15/09/2009 | A Multi-centered, Randomized, Double-blind, Placebo-controlled Clinical Trial to Assess the Efficacy, Safety, and Tolerability of Rasagiline Mesylate 1 mg in Patients with Multiple System Atrophy of the Parkinsonian Subtype (MSA-P) | A Multi-centered, Randomized, Double-blind, Placebo-controlled Clinical Trial to Assess the Efficacy, Safety, and Tolerability of Rasagiline Mesylate 1 mg in Patients with Multiple System Atrophy of the Parkinsonian Subtype (MSA-P) | Multiple System Atrophy of the Parkinsonian Subtype MedDRA version: 12.0;Level: PT;Classification code 10064060;Term: Multiple system atrophy | Trade Name: AZILECT INN or Proposed INN: Rasagiline Other descriptive name: Rasagiline mesylate | Teva Pharmaceutical Industries Ltd | NULL | Not Recruiting | Female: yes Male: yes | 140 | Portugal;France;Hungary;Spain;Austria;Netherlands;Germany;United Kingdom;Italy | |||
| 87 | NCT00977665 (ClinicalTrials.gov) | December 2009 | 15/9/2009 | Clinical Trial to Assess Efficacy, Safety, and Tolerability of Rasagiline Mesylate 1 mg in Patients With Multiple System Atrophy of the Parkinsonian Subtype (MSA-P) | A Multi-centered, Randomized, Double-blind, Placebo-controlled Clinical Trial to Assess the Efficacy, Safety, and Tolerability of Rasagiline Mesylate 1 mg in Patients With Multiple System Atrophy of the Parkinsonian Subtype (MSA-P) | Multiple System Atrophy | Drug: rasagiline mesylate;Drug: placebo | Teva Pharmaceutical Industries | H. Lundbeck A/S | Completed | 30 Years | N/A | All | 174 | Phase 2 | United States;Austria;Canada;France;Germany;Hungary;Israel;Italy;Netherlands;Portugal;Spain;United Kingdom |
| 88 | EUCTR2009-014644-11-FR (EUCTR) | 17/11/2009 | 22/09/2009 | A Multi-centered, Randomized, Double-blind, Placebo-controlled Clinical Trial to Assess the Efficacy, Safety, and Tolerability of Rasagiline Mesylate 1 mg in Patients with Multiple System Atrophy of the Parkinsonian Subtype (MSA-P) | A Multi-centered, Randomized, Double-blind, Placebo-controlled Clinical Trial to Assess the Efficacy, Safety, and Tolerability of Rasagiline Mesylate 1 mg in Patients with Multiple System Atrophy of the Parkinsonian Subtype (MSA-P) | Multiple System Atrophy of the Parkinsonian Subtype MedDRA version: 12.0;Level: PT;Classification code 10064060;Term: Multiple system atrophy | Teva Pharmaceutical Industries Ltd | NULL | Not Recruiting | Female: yes Male: yes | 140 | Phase 2 | Portugal;France;Hungary;Spain;Austria;Netherlands;Germany;United Kingdom;Italy | |||
| 89 | EUCTR2009-016377-15-IT (EUCTR) | 26/10/2009 | 26/10/2009 | DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED TRIAL TO TEST THE EFFICACY, SAFETY AND TOLERABILITY OF LITHIUM IN MULTIPLE SYSTEM ATROPHY - Lithium in MSA | DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED TRIAL TO TEST THE EFFICACY, SAFETY AND TOLERABILITY OF LITHIUM IN MULTIPLE SYSTEM ATROPHY - Lithium in MSA | Muliple system atrophy MedDRA version: 9.1;Level: HLT;Classification code 10008028 | Trade Name: LITIO CARBONATO INN or Proposed INN: LITHIUM CARBONATE | UNIVERSITA` DEGLI STUDI DI NAPOLI FEDERICO II | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | Italy | ||||
| 90 | EUCTR2009-014644-11-ES (EUCTR) | 22/10/2009 | 24/09/2009 | A Multi-centered, Randomized, Double-blind, Placebo-controlled Clinical Trial to Assess the Efficacy, Safety, and Tolerability of Rasagiline Mesylate 1 mg in Patients with Multiple System Atrophy of the Parkinsonian Subtype (MSA-P). Ensayo multicéntrico, randomizado, doble ciego, controlado con placebo para evaluar la eficacia, seguridad y tolerabilidad de mesilato de rasagilina 1 mg en pacientes con Atrofia Multisistémica del subtipo parkinsoniano (MSA-P) | A Multi-centered, Randomized, Double-blind, Placebo-controlled Clinical Trial to Assess the Efficacy, Safety, and Tolerability of Rasagiline Mesylate 1 mg in Patients with Multiple System Atrophy of the Parkinsonian Subtype (MSA-P). Ensayo multicéntrico, randomizado, doble ciego, controlado con placebo para evaluar la eficacia, seguridad y tolerabilidad de mesilato de rasagilina 1 mg en pacientes con Atrofia Multisistémica del subtipo parkinsoniano (MSA-P) | Pacientes con Atrofia Multisistémica del subtipo parkinsoniano (MSA-P) MedDRA version: 12.0;Level: PT;Classification code 10064060;Term: Multiple system atrophy | Teva Pharmaceutical Industries Ltd | NULL | Not Recruiting | Female: yes Male: yes | 140 | Phase 2 | Portugal;France;Hungary;Spain;Austria;Netherlands;Germany;United Kingdom;Italy | |||
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 91 | EUCTR2009-014644-11-HU (EUCTR) | 19/10/2009 | 25/09/2009 | A Multi-centered, Randomized, Double-blind, Placebo-controlled Clinical Trial to Assess the Efficacy, Safety, and Tolerability of Rasagiline Mesylate 1 mg in Patients with Multiple System Atrophy of the Parkinsonian Subtype (MSA-P) | A Multi-centered, Randomized, Double-blind, Placebo-controlled Clinical Trial to Assess the Efficacy, Safety, and Tolerability of Rasagiline Mesylate 1 mg in Patients with Multiple System Atrophy of the Parkinsonian Subtype (MSA-P) | Multiple System Atrophy of the Parkinsonian Subtype MedDRA version: 12.0;Level: PT;Classification code 10064060;Term: Multiple system atrophy | Trade Name: AZILECT INN or Proposed INN: Rasagiline Other descriptive name: Rasagiline mesylate | Teva Pharmaceutical Industries Ltd | NULL | Not Recruiting | Female: yes Male: yes | 140 | Portugal;Hungary;United Kingdom;Germany;Netherlands;France;Spain;Italy;Austria | |||
| 92 | NCT00997672 (ClinicalTrials.gov) | October 2009 | 16/10/2009 | Lithium in Multiple System Atrophy | A Double-blind, Randomized, Placebo-controlled Clinical Trial to Assess Efficacy, Safety and Tolerability of Lithium in Multiple System Atrophy. | Multiple System Atrophy | Drug: Lithium Carbonate;Drug: Placebo | Federico II University | NULL | Terminated | 18 Years | 80 Years | All | 10 | Phase 2 | Italy |
| 93 | EUCTR2007-004890-24-PT (EUCTR) | 07/10/2008 | 25/06/2008 | A Phase II, Randomised, Placebo-Controlled, Double-Blind, Replicated Crossover, Pilot Study on the Effect of Fipamezole on Neurogenic Orthostatic Hypotension in Patients with Multiple System Atrophy or Parkinson’s Disease - FOEHN | A Phase II, Randomised, Placebo-Controlled, Double-Blind, Replicated Crossover, Pilot Study on the Effect of Fipamezole on Neurogenic Orthostatic Hypotension in Patients with Multiple System Atrophy or Parkinson’s Disease - FOEHN | Neurogenic orthostatic hypotension in patients with multiple system atrophy or Parkinson's disease MedDRA version: 9.1;Level: LLT;Classification code 10013113;Term: Disease Parkinson's MedDRA version: 9.1;Classification code 10064060;Term: Multiple system atrophy | Product Name: Fipamezole hydrochloride 90 mg oral disintegrating tablets Product Code: JP-1730/F01 INN or Proposed INN: Fipamezole hydrochloride Product Name: Fipamezole hydrochloride 60 mg oral disintegrating tablets Product Code: JP-1730/F02 INN or Proposed INN: Fipamezole hydrochloride Product Name: Fipamezole hydrochloride 30 mg oral disintegrating tablets Product Code: JP-1730/F03 INN or Proposed INN: Fipamezole hydrochloride | Juvantia Pharma Ltd | NULL | Not Recruiting | Female: yes Male: yes | 24 | Phase 2 | Portugal;France | ||
| 94 | NCT00758849 (ClinicalTrials.gov) | September 2008 | 24/9/2008 | Fipamezole in Neurogenic Orthostatic Hypotension | A Phase II, Randomised, Placebo-Controlled, Double-Blind, Replicated Crossover, Pilot Study on the Effect of Fipamezole on Neurogenic Orthostatic Hypotension in Patients With Multiple System Atrophy or Parkinson's Disease | Symptomatic Neurogenic Orthostatic Hypotension (NOH);Parkinson's Disease;Multiple System Atrophy | Drug: Placebo;Drug: Fipamezole | Juvantia Pharma Ltd | Santhera Pharmaceuticals | Not yet recruiting | 30 Years | 80 Years | Both | 24 | Phase 2 | France;Portugal |
| 95 | NCT00822913 (ClinicalTrials.gov) | June 2008 | 14/1/2009 | Botulinum A Toxin in Patients With Parkinson's Disease | The Use of Toxin Botulinum A Toxin in Patients With Parkinson's Disease and Multiple System Disease, Affected by Refractory Detrusor Overactivity. | Parkinson's Disease;Multiple System Atrophy;Detrusor Overactivity | Drug: Intravesical injection of Botulinum A toxin | University Of Perugia | University of Roma La Sapienza | Enrolling by invitation | 18 Years | 80 Years | Both | 20 | Phase 4 | NULL |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 96 | NCT00750867 (ClinicalTrials.gov) | June 2008 | 9/9/2008 | Treatment of Multiple System Atrophy Using Intravenous Immunoglobulins | Treatment of Multiple System Atrophy Using Intravenous Immunoglobulins | Multiple System Atrophy | Drug: intravenous immunoglobulin (IVIg) | University of Massachusetts, Worcester | NULL | Completed | 18 Years | N/A | All | 9 | Phase 2 | United States |
| 97 | EUCTR2007-004890-24-FR (EUCTR) | 07/05/2008 | 09/05/2008 | A Phase II, Randomised, Placebo-Controlled, Double-Blind, Replicated Crossover, Pilot Study on the Effect of Fipamezole on Neurogenic Orthostatic Hypotension in Patients with Multiple System Atrophy or Parkinson’s Disease - FOEHN | A Phase II, Randomised, Placebo-Controlled, Double-Blind, Replicated Crossover, Pilot Study on the Effect of Fipamezole on Neurogenic Orthostatic Hypotension in Patients with Multiple System Atrophy or Parkinson’s Disease - FOEHN | Neurogenic orthostatic hypotension in patients with multiple system atrophy or Parkinson's disease MedDRA version: 9.1;Level: LLT;Classification code 10013113;Term: Disease Parkinson's MedDRA version: 9.1;Classification code 10064060;Term: Multiple system atrophy | Product Name: Fipamezole hydrochloride 90 mg oral disintegrating tablets Product Code: JP-1730/F01 INN or Proposed INN: Fipamezole hydrochloride Product Name: Fipamezole hydrochloride 60 mg oral disintegrating tablets Product Code: JP-1730/F02 INN or Proposed INN: Fipamezole hydrochloride Product Name: Fipamezole hydrochloride 30 mg oral disintegrating tablets Product Code: JP-1730/F03 INN or Proposed INN: Fipamezole hydrochloride | Juvantia Pharma Ltd | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 24 | Phase 2 | Portugal;France | ||
| 98 | NCT01146548 (ClinicalTrials.gov) | May 2008 | 16/6/2010 | Fluoxetine in Multiple System Atrophy Patients | Assessment of Fluoxetine's Effect in Patients With Multiple System Atrophy : a Double Blind Placebo-controlled Randomized Trial | Multiple System Atrophy | Drug: FLUOXETINE | University Hospital, Toulouse | Clinical Research Center, Toulouse | Completed | 30 Years | 80 Years | Both | 87 | Phase 2 | France |
| 99 | NCT00911365 (ClinicalTrials.gov) | May 2008 | 26/5/2009 | Trial of Autologous Mesenchymal Stem Cells in Patients With Multiple System Atrophy | A Double-blind Placebo-controlled Randomized Clinical Trial of Autologous Mesenchymal Stem Cells in Patients With Multiple System Atrophy | Multiple System Atrophy | Biological: autologous mesenchymal stem cells;Biological: normal saline | Yonsei University | NULL | Completed | N/A | 75 Years | Both | 27 | Phase 2 | Korea, Republic of |
| 100 | EUCTR2007-004922-26-FR (EUCTR) | 12/02/2008 | 31/01/2008 | Evaluation de l’effet de la fluoxétine chez le patient atteint d’atrophie multi-systématisée : Etude randomisée en double-insu versus placebo. - Etude MSA-fluoxétine | Evaluation de l’effet de la fluoxétine chez le patient atteint d’atrophie multi-systématisée : Etude randomisée en double-insu versus placebo. - Etude MSA-fluoxétine | atrophie multisystématisée MedDRA version: 9.1;Level: LLT;Classification code 10064060;Term: Multiple system atrophy | Trade Name: PROZAC | CHU Toulouse | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | France | ||||
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 101 | NCT00738062 (ClinicalTrials.gov) | January 2008 | 19/8/2008 | Open-Label Clinical Study of Droxidopa in Patients With Neurogenic Orthostatic Hypotension (NOH) | An Open-label Study, to Assess the Long-term Safety and Clinical Benefit of Droxidopa in Subjects With PAF, Dopamine Beta Hydroxylase Deficiency or Non-diabetic Neuropathy and Symptomatic Neurogenic Orthostatic Hypotension | Neurogenic Orthostatic Hypotension;Non-Diabetic Autonomic Neuropathy;Multiple System Atrophy;Dopamine Beta Hydroxylase Deficiency | Drug: Droxidopa;Drug: Placebo | Chelsea Therapeutics | NULL | Completed | 18 Years | N/A | All | 103 | Phase 3 | United States;Australia;Canada;New Zealand |
| 102 | NCT00547911 (ClinicalTrials.gov) | October 2007 | 19/10/2007 | Augmenting Effects of L-DOPS With Carbidopa and Entacapone | L-Dihydroxyphenylserine (L-DOPS) for Norepinephrine Deficiency: Interactions With Carbidopa and Entacapone | Parkinson Disease;Multiple System Atrophy;Autonomic Nervous System Diseases | Drug: Droxidopa;Drug: Carbidopa;Drug: Entacapone | National Institute of Neurological Disorders and Stroke (NINDS) | NULL | Terminated | 18 Years | N/A | All | 14 | Phase 1;Phase 2 | United States |
| 103 | NCT00103597 (ClinicalTrials.gov) | January 2005 | 11/2/2005 | Efficacy of Therapeutic Interventions for Orthostatic Hypotension in Parkinson's Disease and Multiple System Atrophy | Efficacy of Therapeutic Interventions for Orthostatic Hypotension in Parkinson's Disease and Multiple System Atrophy | Parkinson's Disease;Multiple System Atrophy;Orthostatic Hypotension | Drug: Fludrocortisone;Drug: Domperidone;Behavioral: Conservative Measures for Orthostatic Hypotension | Royal Brisbane and Women's Hospital | NULL | Completed | 40 Years | 95 Years | Both | 50 | Phase 1 | Australia |
| 104 | NCT00179023 (ClinicalTrials.gov) | April 2003 | 13/9/2005 | The Autonomic Nervous System and Obesity | The Autonomic Nervous System and Obesity | OBESITY;HYPERTENSION;PURE AUTONOMIC FAILURE;SHY-DRAGER SYNDROME | Drug: Trimethaphan;Drug: Pseudoephedrine | Vanderbilt University | NULL | Completed | 18 Years | 80 Years | All | 128 | Phase 1 | United States |
| 105 | NCT01044992 (ClinicalTrials.gov) | May 2002 | 6/1/2010 | Motor Activation in Multiple System Atrophy and Parkinson Disease: a Positron Emission Tomography (PET) Study | Motor Activation in Patients With Multi Systemic Atrophy and Comparison With Parkinson Disease and Dopaminergic Challenge | Multisystemic Atrophy | Radiation: H215O PET;Drug: Levodopa | University Hospital, Toulouse | NULL | Completed | 40 Years | 75 Years | Both | 38 | N/A | France |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 106 | NCT00211224 (ClinicalTrials.gov) | April 2000 | 13/9/2005 | Neuroprotection and Natural History in Parkinson's Plus Syndromes (NNIPPS) | Phase 3 Study of Riluzole in Multiple System Atrophy (MSA) and Progressive Supranuclear Palsy (PSP) (Parkinson's Plus Syndromes) | Multiple System Atrophy;Progressive Supranuclear Palsy | Drug: Riluzole | King's College London | Assistance Publique - Hôpitaux de Paris;University of Ulm;Aventis Pharmaceuticals | Terminated | 30 Years | 80 Years | Both | 800 | Phase 3 | United Kingdom |
| 107 | NCT00004478 (ClinicalTrials.gov) | March 1999 | 18/10/1999 | Droxidopa in Treating Patients With Neurogenic Hypotension | Study of Droxidopa in Patients With Neurologic Hypotension | Shy-Drager Syndrome;Orthostatic Hypotension | Drug: droxidopa | Mount Sinai School of Medicine | NULL | Completed | 20 Years | N/A | Both | N/A | United States |